TNFRSF10B (DR5): A Central Regulator in Apoptosis, Tumor Progression, and Targeted Therapy

Published by ANT BIO PTE. LTD.

Concept Overview

TNFRSF10B, commonly referred to as DR5 or TRAIL‑R2, is a type I transmembrane death receptor belonging to the tumor necrosis factor receptor superfamily. It functions as a key molecular switch for apoptosis, immune regulation, and tumor‑related signaling. Composed of 468 amino acids, this receptor contains an extracellular cysteine‑rich domain (CRD1–4), a transmembrane segment, and an intracellular death domain (DD). Its physiological roles range from embryonic development and immune homeostasis to pathological conditions such as cancer, inflammation, and autoimmune disorders.

Research Frontiers

Recent investigations have redefined TNFRSF10B as a multifunctional signaling hub rather than merely a death inducer. Structural studies confirm that TNFRSF10B trimerizes upon binding its ligand TRAIL, with CRD2 and CRD3 serving as the primary ligand‑binding interfaces. Expression of the TNFRSF10B gene, located on human chromosome 8p21.3, is tightly controlled by transcription factors including p53, NF‑κB, and E2F1. Epigenetic modifications—especially promoter methylation—are now recognized as major mechanisms underlying dysregulated expression in cancer.

Scientists continue to uncover non‑apoptotic functions of TNFRSF10B, including the activation of NF‑κB, MAPK, and inflammatory cascades that influence cell survival, invasion, and immune cell polarization. Its alternatively spliced isoforms, such as the death‑domain‑deficient DcR2, act as decoy receptors that fine‑tune signal output and therapy resistance.

Research Significance

TNFRSF10B represents a high‑priority therapeutic target due to its ability to selectively trigger apoptosis in tumor cells while sparing most normal tissues. Dysregulation of TNFRSF10B is widely implicated in oncogenesis, metastasis, and chemotherapy resistance. Meanwhile, its roles in immune cell homeostasis, neutrophil clearance, and antiviral immunity make it relevant to inflammatory diseases, autoimmune disorders, and infectious diseases.

Clinically, TNFRSF10B expression status and promoter methylation serve as prognostic and predictive biomarkers. Agonistic antibodies, bispecific constructs, and small‑molecule activators directed against TNFRSF10B are under intense clinical development for solid and hematological malignancies.

Related Mechanisms and Research Applications

Signaling Mechanisms

1. Canonical apoptotic signaling

TRAIL binding induces conformational changes in the death domain of TNFRSF10B, leading to the recruitment of FADD and the formation of the death‑inducing signaling complex (DISC). This activates caspase‑8, which initiates either direct caspase‑3‑mediated apoptosis (Type I cells) or mitochondrial amplification via tBid and cytochrome c release (Type II cells).

2. Non‑apoptotic signaling

Through RIPK1 and TRAF2, TNFRSF10B can activate NF‑κB and MAPK pathways to promote cell survival, migration, inflammation, and angiogenesis in a context‑dependent manner.

3. Immune modulation

TNFRSF10B regulates CD8+ T‑cell cytotoxicity, NK‑cell‑mediated surveillance, Treg function, and macrophage polarization. It also modulates the resolution of inflammation by controlling neutrophil apoptosis.

Research Methods Supported by ANT BIO PTE. LTD. Products

Researchers worldwide rely on high‑quality reagents to explore TNFRSF10B expression, regulation, signaling, and therapeutic responses.

• Antibody‑based assays: Western blot, flow cytometry, immunohistochemistry, and immunofluorescence using targeted antibodies
• Protein‑based studies: Recombinant TRAIL and TNFRSF10B proteins for ligand‑receptor interaction analysis
• Detection kits: ELISA kits for quantifying soluble or cellular TNFRSF10B levels
• General reagents: buffers, dilution agents, and secondary antibodies for consistent experimental results

Brand Mission

ANT BIO PTE. LTD. is committed to empowering life science researchers with premium, consistent, and reliable reagents to accelerate discoveries in apoptosis, immunology, oncology, and translational medicine. We support every stage of research—from basic mechanistic studies to clinical biomarker development and therapeutic screening.

Featured Related Products

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.